New anti-clotting drug more effective than current treatment

March 11, 2013

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.

Researchers report that the new , which is administered intravenously, reduced the odds of complications from stenting procedures. Specifically, those who received cangrelor had a lower combined incidence of death, , ischemia-driven , or stent thrombosis at 48 hours after .

"We are very excited about the potential for this new medication to reduce complications in patients receiving coronary stents for a wide variety of indications. In addition to being much quicker to take effect and more potent than currently available treatment options, this is reversible and has a fast offset of action, which could be an advantage if is needed." said Deepak L. Bhatt, MD, MPH, lead author of the study, director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital (BWH) and chief of cardiology at VA Boston Healthcare System, as well as professor of medicine at Harvard Medical School.

In this randomized double-blind trial, researchers compared the novel IV drug cangrelor against the oral clopidogrel standard of care in approximately 11,000 patients at 153 centers around the world. The study included a wide selection of patients with different types of heart attack, angina, and other conditions for which people undergo percutaneous (PCI), as long as they did not have high risk for bleeding or recent exposure to other anti-clotting drugs.

Researchers report significantly better performance by cangrelor compared with clopidogrel:

  • A 22 percent reduction in the odds of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization: 4.7 percent vs. 5.9 percent
  • A 38 percent reduction in the odds of stent thrombosis at 48 hours: 0.8 percent vs. 1.4 percent
  • Both treatment arms showed a quite low, statistically comparable incidence in severe bleeding at 48 hours: 0.16 percent vs. 0.11 percent.
Coronary artery stents are used in the majority of patients who undergo percutaneous coronary intervention (PCI), a common medical procedure used to treat arteries in the heart that have become narrowed or blocked due to coronary artery disease, which affects an estimated 14 million Americans. During this procedure, patients are regularly given oral doses of an anti-clotting agent to prevent blood clotting. Both cangrelor and interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting.

"We are encouraged by these compelling results, especially as it relates to the safety data, and believe that this drug has the potential to offer dramatic benefits to our patients" said Robert A. Harrington, M.D., chairman of medicine at Stanford University School of Medicine and co-chair of the study.

The company plans to file for approval with the Food and Drug Administration using data from CHAMPION PHOENIX and the earlier BRIDGE trial.

Explore further: Novel anti-clotting drug more effective than Plavix in coronary procedures, study says

Related Stories

Novel anti-clotting drug more effective than Plavix in coronary procedures, study says

March 11, 2013
(Medical Xpress)—An experimental drug has been shown to be significantly more effective at preventing blood clots during coronary stenting procedures compared to the anti-clotting agent now typically used, according to ...

Complications in patients undergoing percutaneous coronary intervention tend to occur within first 30 days

March 24, 2012
Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a ...

Results of the BRIDGE trial reported at TCT 2011

November 9, 2011
Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented ...

Drug helps maintain platelet inhibition and anti-clotting levels prior to cardiac surgery

January 17, 2012
Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.